The estrogen plus progestin trial was stopped in July 2002, after investigators found that the associated health risks of the combination hormone therapy outweighed the benefits. Participants were followed for an average of 5.6 years.

Selected Findings

Health Risks and Benefits 3 Years After Stopping (March 2008)

• Summary of Results
• Health Risks and Benefits 3 Years After Stopping, JAMA March 4, 2008

Venous Thrombosis (October 2004)

• Summary of Results
• Estrogen Plus Progestin and Risk of Venous Thrombosis, JAMA October 6, 2004

Colorectal Cancer (March 2004)

• Summary of Results
• Questions and Answers About the Colorectal Cancer Findings
• Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women, NEJM March 4, 2004

Peripheral Arterial Disease Risk (February 2004)

• Summary of Results
• Estrogen plus Progestin and the Risk of Peripheral Arterial Disease, Circulation, February 10, 2004

Fracture Risk and Bone Mineral Density (October 2003)

• Summary of Results
• Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density, JAMA, October 1, 2003

Gynecologic Cancers and Diagnostic Procedures (October 2003)

• Summary of Results
• Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures, JAMA, October 1, 2003

Coronary Heart Disease Risk (August 2003)

• Summary of Results
• Questions and Answers About the Coronary Heart Disease Findings
• Estrogen plus Progestin and the Risk of Coronary Heart Disease, NEJM, August 7, 2003
• From Presumed Benefit to Potential Harm--Hormone Therapy and Heart Disease (Perspective), NEJM, August 7, 2003
• Hormone-Replacement Therapy and Cardiovascular Diseases (Perspective), NEJM, August 7, 2003

Breast Cancer Risk (June 2003)

• Summary of Results
• National Cancer Institute Postmenopausal Hormone Use Fact Sheet (updated)
• Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women, JAMA, June 25, 2003
• Relationship Between Long Durations and Different Regimens of Hormone Therapy and Risk of Breast Cancer, JAMA, June 25, 2003
• Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword (Editorial), JAMA, June 25, 2003

Dementia and Cognitive Function -- Women's Health Initiative Memory Study (May 2003)

• Press release: Rates of Dementia Increase Among Older Women on Combination Hormone Therapy, May 27, 2003
• Questions and Answers About the Women's Health Initiative Memory Study
• Women's Health Initiative Memory Study Web site
• FDA Talk Paper
• Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women, JAMA, May 28, 2003
• Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women, JAMA, May 28, 2003
• Hormone Therapy and the Brain Ç D»j› vu All Over Again? (Editorial), JAMA, May 28, 2003

Stroke Risk (May 2003)

• Summary of Results
• Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women, JAMA, May 28, 2003

Quality of life (March 2003)

• Effects of Estrogen Plus Progestin on Health-Related Quality of Life, NEJM (online), March 17, 2003
• Summary of Results

Risks and Benefits of Combination Therapy (July 2002)

• Press Release: NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit, July 9, 2002
• Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women, JAMA, July 17, 2002
• Failure of Estrogen Plus Progestin Therapy for Prevention (Editorial), JAMA, July 17, 2002
• NHLBI Media Kit